Literature DB >> 19608058

Vitiligo update.

Rebat M Halder1, Johnathan L Chappell.   

Abstract

Vitiligo is an acquired dyschromia of the skin in which there is a loss of epidermal melanocytes. The prevalence of vitiligo is approximately 1% in the United States and 0.1-2% worldwide. The exact pathogenesis of vitiligo remains elusive and is likely multifactorial. After completing this update, participants should be able to discuss the epidemiology of vitiligo and summarize the proposed mechanisms for development of this disease. In addition, they should be able to discuss physical findings, approach to the patient, and some of the therapeutic modalities for this disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608058     DOI: 10.1016/j.sder.2009.04.008

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  19 in total

Review 1.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  Association study between polymorphisms of CD28, CTLA4 and ICOS and non-segmental vitiligo in a Korean population.

Authors:  Min Kyung Shin; So Hee Im; Hae Jeong Park; Su Kang Kim; Sung Vin Yim; Joo-Ho Chung; Mu-Hyoung Lee
Journal:  Exp Ther Med       Date:  2011-08-03       Impact factor: 2.447

3.  Segmental vitiligo in a patient with thoracic outlet syndrome.

Authors:  Murat Kara; Sinan Yılmaz; Özgür Kara; Mehmet Güney Şenol; Fatih Özdağ; Levent Özçakar
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

4.  Serum Zinc and Inflammatory Cytokines in Vitiligo.

Authors:  Eman Mostafa Sanad; Asmaa Adel El-Fallah; Ahmed Raad Al-Doori; Rehab Mohammed Salem
Journal:  J Clin Aesthet Dermatol       Date:  2020-12-01

5.  Tumor necrosis factor-α -308G/A polymorphism is associated with active vitiligo vulgaris in a northeastern Mexican population.

Authors:  Mauricio Salinas-Santander; Daniel Díaz-García; Augusto Rojas-Martínez; Cristina Cantú-Salinas; Celia Sánchez-Domínguez; Miguel Reyes-López; Ricardo M Cerda-Flores; Jorge Ocampo-Candiani; Rocío Ortiz-López
Journal:  Exp Ther Med       Date:  2012-03-09       Impact factor: 2.447

Review 6.  Melanocyte stem cells as potential therapeutics in skin disorders.

Authors:  Ju Hee Lee; David E Fisher
Journal:  Expert Opin Biol Ther       Date:  2014-08-08       Impact factor: 4.388

7.  Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.

Authors:  A Ruiz-Argüelles; M García-Carrasco; G Jimenez-Brito; S Sánchez-Sosa; B Pérez-Romano; J Garcés-Eisele; C Camacho-Alarcón; V Reyes-Núñez; M Sandoval-Cruz; C Mendoza-Pinto; A López-Colombo
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

8.  Apigenin protects human melanocytes against oxidative damage by activation of the Nrf2 pathway.

Authors:  Baoxiang Zhang; Jing Wang; Guodong Zhao; Mao Lin; Yong Lang; Diancai Zhang; Dianqin Feng; Caixia Tu
Journal:  Cell Stress Chaperones       Date:  2020-01-18       Impact factor: 3.667

9.  Strict Anatomical Colocalization of Vitiligo and Elastolytic Granulomas.

Authors:  N Merino de Paz; M Rodríguez-Martín; M García Bustínduy; A Martín-Herrera; A Noda-Cabrera
Journal:  Case Rep Dermatol       Date:  2010-02-05

10.  Acute toxicity and the 28-day repeated dose study of a Siddha medicine Nuna Kadugu in rats.

Authors:  Ramaswamy Selvaratnam Ramaswamy; Nettam Prathyusha; Ruthiramoorthi Saranya; Haridass Sumathy; Kutuva Tulasi Mohanavalli; Raju Jyothi Priya; Jayakothanda Ramaswamy Venkhatesh; Chidambaram Saravana Babu; Kumarasamy Manickavasakam; Sadagopan Thanikachalam
Journal:  BMC Complement Altern Med       Date:  2012-10-22       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.